No Prescription |
 |
 | ||
|
ETOSID VP 16 |
|
| ||
No Prescription » Prescription Drugs 7 » ETOSID VP 16 This medication is used to treat: testicular cancer lung cancer This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.Etoposide is in a class of drugs known as podophyllotoxin derivatives; it slows or stops the growth of cancer cells in your body. The length of treatment depends on the types of drugs you are taking how well your body responds to them and the type of cancer you have.Etoposide also is used to treat non-Hodgkin's lymphomas mycosis fungoides Hodgkin's disease acute myelogenous leukemia acute lymphocytic leukemia chronic myelogenous leukemia Wilms' tumor neuroblastoma Kaposi's sarcoma related to acquired immune deficiency syndrome (AIDS) gestational trophoblastic tumors ovarian germ-cell tumors hepatoma Ewing's sarcoma rhabdomyosarcoma brain tumors and refractory advanced breast cancer. High doses of etoposide along with other chemotherapy drugs have been used with autologous bone marrow transplant for refractory advanced malignant neoplasms. Talk to your doctor about the possible risks of using this drug for your condition. Buy ETOSID VP 16 and other Prescription Drugs 7 products online at Medstore. 714
About ETOSID VP 16: Product Type: Prescription Drugs 7 ETOSID ( VP-16 VePesid Oral Generic Etoposide ) ETOSID (VP-16 VePesid Oral Generic Etoposide) VP-16 VePesid Oral Generic Etoposide 50mg Caps 28 (7 x 4) VP-16 VePesid Oral Generic Etoposide ETOSID
View more Prescription Drugs 7 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
